Skip to Main Content
Due to a lapse in federal funding, this USDA website will not be actively updated. Once funding has been reestablished, online operations will continue.
Biomarker metabolite signatures pave the way for electronic-nose applications in early clinical disease diagnosesAuthor(s): Alphus Dan Wilson
Source: Current Metabolomics
Publication Series: Scientific Journal (JRNL)
Station: Southern Research Station
View PDF (2.0 MB)
DescriptionBackground: Analysis of volatile metabolites derived from the human breath or biofluids provides noninvasive means of detecting and monitoring diseases that occur throughout the body. Diseases arise from different mechanisms that cause alterations in normal physiological processes. Mechanisms of disease (pathogenesis) result in the production of unique mixtures of abnormal volatile organic compounds (VOCs), referred to as disease biomarker metabolites when associated with specific
diseases. Regardless of where disease biomarkers originate in the body, they are picked up by the circulatory system and eventually expelled out through the lungs. Analysis of complex mixtures of disease biomarkers provides effective diagnostic clues for detecting the presence of specific disease processes occurring in the body.
Methods: Recent progress in the development of electronic-nose (e-nose) applications and technologies for clinical examinations and human disease diagnoses are reviewed.
Results: Metabolomics has been useful in identifying biomarkers and mechanisms of disease, but is often time-consuming and not easily applied to disease diagnosis. E-nose devices are relatively new gas-sensing technologies that are small, simple, portable and particularly useful for noninvasive early disease detection. Some major advantages of using e-noses for disease diagnoses are that they provide quicker, more efficient diagnostic results and cause less stress, anxiety, and no pain to patients.
Conclusion: Recent advancements in the use of e-nose devices to detect complex mixtures of disease biomarkers are providing the great potential for these instruments to facilitate and accelerate point-ofcare clinical disease diagnoses.
- You may send email to firstname.lastname@example.org to request a hard copy of this publication.
- (Please specify exactly which publication you are requesting and your mailing address.)
- We recommend that you also print this page and attach it to the printout of the article, to retain the full citation information.
- This article was written and prepared by U.S. Government employees on official time, and is therefore in the public domain.
CitationWilson, Alphus Dan . 2017.Biomarker metabolite signatures pave the way for electronic-nose applications in early clinical disease diagnoses. Current Metabolomics. 5(2):90-101. 12 p. https://doi.org/10.2174/2213235X04666160728161251.
KeywordsAroma signature patterns, breathprints, disease biomarkers, electronic aroma detection, e-nose, metabolomics.
- Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath
- Recent progress in the design and clinical development of electronic-nose technologies
- Application of electronic-nose technologies and VOC-biomarkers for the noninvasive early diagnosis of gastrointestinal diseases
XML: View XML